$7.96-0.14 (-1.73%)
Avantor, Inc.
Avantor, Inc. in the Healthcare sector is trading at $7.96. The stock is currently near its 52-week low of $7.26, remaining 29.0% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why AVTR maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle Ea...
ESAB Corp. (NYSE:ESAB) is one of the best up and coming stocks with highest upside potential. On April 2, ESAB appointed R. Brent Jones as Chief Financial Officer, effective in early May. Jones, a highly experienced executive with over 30 years of financial leadership, succeeds Kevin Johnson, who is departing to join a private firm. […]
Avantor, Inc. (NYSE:AVTR) is one of the 10 Best Medical Stocks to Buy Under $30. On April 1, William Blair reaffirmed its Market Perform rating on Avantor, Inc. (NYSE:AVTR) after the company announced the departure of its Chief Financial Officer, Brent Jones. Jones will leave Avantor, Inc. (NYSE:AVTR) on or before June 24. Despite this […]
AVTR benefits from stable Q1 revenues and improving demand trends, though margin pressure and volume softness weigh on profitability.
Avantor (NYSE:AVTR) said first-quarter 2026 results came in ahead of internal expectations, driven by improved execution in its Bioscience & Medtech Products (BMP) segment and early progress from its “Revival” operational and commercial program. Management reaffirmed full-year guidance and said
Emmanuel Ligner: Good morning, and thank you for joining us today. First quarter results exceeded our expectations due to improved execution in BioScience and Medtech product segments, and we have reaffirmed our full year guidance. VWR Distribution and Services generated $1.15 billion of revenue in the first quarter, down 5% organically versus the prior year.